Myelo Therapeutics conducts successful Pre-IND meeting with FDA
Completes new financing round
22-Jun-2017 -
Myelo Therapeutics GmbH announced that it successfully conducted a Pre-IND (Investigational New Drug) meeting with the FDA Center for Drug Evaluation and Research (CDER) on May 11th, 2017 for Myelo001, a novel, orally bioavailable small molecule to prevent myelosuppression caused by chemotherapy. ...
breast cancer
chemotherapy
neutropenia
+1